C5AR2 and neoplasm: Interestingly, this study also demonstrated that an anti-GPR-77 antibody in combination with docetaxel therapy exerted anti-tumor efficacy comparable to that induced by the combination anti-IL-6/anti-IL-8 therapy, which significantly reduced the number of CD10+GPR-77+ CAFs and the proportion of CSCs in the treated tumors (72).